Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 708 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IT Injection Clear all
Completed Phase 2 Interventional Results available

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

NCT03007979
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Cancer of Breast, Malignant Tumor of Breast
Interventions
Palbociclib, Letrozole, Fulvestrant, Optional research biopsy, Goserelin, Research blood draw, Circulating tumor cell blood draw, Tumor biopsy (optional)
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
St Louis, Missouri • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 23, 2026, 10:45 AM EDT
Not listed Phase 4 Interventional

A Comparison of Ultrasound-guided Steroid Injection With Wrist Splint in Carpal Tunnel Syndrome

NCT04515966
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Methylprednisolone Injection [Solu-Medrol], wrist splint
Drug · Device
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boardman, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Oct 23, 2026, 10:45 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

3D Video Virtual Reality Exposure Therapy Study

NCT02584387
View directory record Official record
Conditions
Acrophobia, Arachnophobia
Interventions
3D Video Virtual Reality Exposure Therapy
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Results available

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

NCT03010176
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
Ulevostinag, Pembrolizumab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Santa Monica, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting Phase 1 Interventional

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

NCT06171750
View directory record Official record
Conditions
Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor, Solid Tumor, Metastatic Solid Tumor, Metastasis to Soft Tissue, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma
Interventions
tolododekin alfa, Cemiplimab
Drug
Lead sponsor
Ankyra Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Bethesda, Maryland • Boston, Massachusetts • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Terminated Phase 3 Interventional Results available

Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System

NCT03643562
View directory record Official record
Conditions
Niemann-Pick Type C Disease
Interventions
Adrabetadex
Drug
Lead sponsor
Mandos LLC
Industry
Eligibility
4 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 23, 2026, 10:45 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

RHA® Redensity With New Anesthetic Agent Perioral Rhytids (PAS)

NCT06378086
View directory record Official record
Conditions
Pain, Aging
Interventions
RHA® Redensity with new anesthetic agent, RHA® Redensity with lidocaine
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting Phase 2 Interventional

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

NCT07060001
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)
Interventions
5hmC Biomarker, Venetoclax, Decitabine 20 mg/m²/day for 5 days, Azacitidine (AZA), Cytarabine (Ara-C), Anthracycline
Diagnostic Test · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Terminated Not applicable Interventional

Breathing Synchronized PET/CT Scans for the Detection of Malignant Lung & Liver Lesions and Assessment of Tumor Glycolysis

NCT01052766
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer
Interventions
PET/CT and BH PET/CT
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Not applicable Interventional Results available

TEOSYAL® RHA Ultra Deep and Perlane-L® for the Correction of Nasolabial Folds

NCT02253147
View directory record Official record
Conditions
Nasolabial Folds, Wrinkles
Interventions
TEOSYAL® RHA Ultra Deep
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Beverly Hills, California • Bradenton, Florida • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18

NCT00500058
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
SB-485232, Rituximab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Chicago, Illinois • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting Phase 1 Interventional

Study of PAT in Patients With Solid Tumor Cancers

NCT05338658
View directory record Official record
Conditions
Metastasis, Solid Tumor
Interventions
Peptide Alarm Therapy (PAT)
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 23, 2026, 10:45 AM EDT
Terminated Phase 2 Interventional Results available

A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)

NCT01565148
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
iCo-007 350 mcg, iCo-007 700 mcg, iCo-007 350 mcg and Laser, Ranibizumab and iCo-007 350 mcg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

NCT04083235
View directory record Official record
Conditions
Metastatic Adenocarcinoma of the Pancreas
Interventions
Irinotecan Liposomal Injection, Oxaliplatin, 5Fluorouracil, Leucovorin, Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
72
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement

NCT01949155
View directory record Official record
Conditions
Otitis Media With Effusion
Interventions
OTO-201, Sham
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2016 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

NCT00440726
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Bortezomib, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Vincristine, Triple IT Therapy
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Duarte, California • Long Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 23, 2026, 10:45 AM EDT
Enrolling by invitation Phase 2 Interventional

Daratumumab in HLA Desensitization Prior to Transplantation

NCT05300451
View directory record Official record
Conditions
Cardiac Transplant
Interventions
Daratumumab and hyaluronidase-fihj
Biological
Lead sponsor
Barry A. Boilson
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Recruiting Phase 2Phase 3 Interventional

Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy

NCT06721520
View directory record Official record
Conditions
Esophageal Cancer Surgery, Esophagectomy, Delayed Gastric Emptying Following Procedure, Esophageal Diseases, Esophageal Achalasia, Pylorus Dysfunction, Esophageal Dysmotility
Interventions
Botulinum Toxin A (Botox ), Pyloromyotomy
Biological · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age

NCT06546423
View directory record Official record
Conditions
Human Metapneumovirus, Human Parainfluenza Virus Type 3
Interventions
B/HPIV3/HMPV-PreF-A vaccine, B/HPIV3/HMPV-F-B365 vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
24 Months to 59 Months
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Baltimore, Maryland • Columbia, Maryland • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Terminated Phase 4 Interventional

Platelet-rich Plasma, Corticosteroid, or Lidocaine for Acromioclavicular Joint Pain

NCT05161468
View directory record Official record
Conditions
Acromioclavicular Sprain
Interventions
Lidocaine injection, Corticosteroid Injection, Protein Rich Plasma(PRP) Injection
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
San Antonio, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

NCT04640168
View directory record Official record
Conditions
COVID-19
Interventions
Baricitinib, Dexamethasone, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
61
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 23, 2026, 10:45 AM EDT
Active, not recruiting Phase 2 Interventional

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

NCT02923778
View directory record Official record
Conditions
Leiomyosarcoma, Liposarcoma, Sarcoma G2, Sarcoma G3, Soft Tissue Sarcoma, Soft Tissue Sarcoma of the Trunk and Extremities, Stage I Soft Tissue Sarcoma AJCC v7, Stage II Soft Tissue Sarcoma AJCC v7, Undifferentiated Pleomorphic Sarcoma
Interventions
Biopsy Procedure, Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, Talimogene Laherparepvec
Procedure · Radiation · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
16
States / cities
Phoenix, Arizona • Duarte, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer

NCT00069108
View directory record Official record
Conditions
Colorectal Cancer
Interventions
5 FU, Leucovorin, Oxaliplatin, capecitabine [Xeloda]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
8
States / cities
Bakersfield, California • Colorado Springs, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2016 · Synced Oct 23, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Safety Study of Seasonal Influenza Vaccine by Jet Injection

NCT00987350
View directory record Official record
Conditions
Healthy Adults
Interventions
LectraJet, TIV by jet injection, Seasonal Trivalent Influenza Vaccine
Device · Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 23, 2026, 10:45 AM EDT